Search
Belumosudil
go.drugbank.com/drugs/DB16703ApprovedInvestigational[A236644,L34759] Belumosudil was first approved by the FDA in July 2021, under the brand name Rezurock, for the treatment of chronic GVHD in patients who have tried and failed at least two prior lines … [L34749] In the treatment of GVHD, a condition in which donor T-cells begin to attack recipient tissues following allogeneic hematopoeitic stem cell transplantation (HSCT), belumosudil helps to resolve
Lenalidomide
go.drugbank.com/drugs/DB00480ApprovedInvestigationalzone lymphoma in selected patients. … [A228553] It is a 4-amino-glutamyl analogue of [thalidomide] [A228543] and like thalidomide, lenalidomide exists as a racemic mixture of the active S(-) and R(+) forms.
Products: LENALIDOMIDE DR. REDDY'STelmisartan
go.drugbank.com/drugs/DB00966ApprovedInvestigationalsmooth muscle, ultimately leading to a reduction in arterial blood pressure. … Telmisartan is an angiotensin II receptor antagonist (ARB) used in the management of hypertension.
Synonyms: 4'-((1,4'-dimethyl-2'-propyl(2,6'-bi-1H-benzimidazol)-1'-yl)methyl)-(1,1'-biphenyl)-2-carboxylic acid, 4'-[(1,4'-dimethyl-2'propyl[2,6'-bi-1H-benzimidazol]-1'-yl)methyl]-[1,1'-biphenyl]-2-carboxylic acidMixtures: SYNTHESIS CORDIAX D, CORDIAX D FORTE COMPRIMIDOSEconazole
go.drugbank.com/drugs/DB01127ApprovedA broad spectrum antimycotic with some action against Gram positive bacteria. It is used topically in dermatomycoses also orally and parenterally.
Lumacaftor
go.drugbank.com/drugs/DB09280ApprovedInvestigationalresults in impaired production of the CFTR protein, thereby causing a significant reduction in the amount of ion transporter present on cell membranes. … Lumacaftor is a drug used in combination with [DB08820] as the fixed dose combination product Orkambi for the management of Cystic Fibrosis (CF) in patients aged 6 years and older.
Strontium ranelate
go.drugbank.com/drugs/DB09267ApprovedWithdrawnStrontium ranelate, a strontium (II) salt of ranelic acid, is a medication for osteoporosis. … It is therefore promoted as a "dual action bone agent" (DABA) indicated for use in treatment of severe osteoporosis.
Mixtures: STRODAY D3 2G/800 IU SAŞE , 28 SAŞE, FULLBONE D3 2 G/800 IU EFERVESAN TABLET, 30 ADETRelacorilant
go.drugbank.com/drugs/DB14976ApprovedInvestigationalRelacorilant is a first-in-class, selective glucocorticoid receptor antagonist. … [L56089] Relacorilant was approved by the US FDA on March 25, 2026, for use in combination with [paclitaxel] in patients with certain platinum-resistant cancers.[L56093,L56089]
Amivantamab
go.drugbank.com/drugs/DB16695ApprovedInvestigationalFDA approved the subcutaneous formulation, RYBREVANT FASPRO™, across all existing and expanded indications of amivantamab, including its use as a first-line, chemotherapy-free combination regimen with … [A235103,A235123] Patients with NSCLC with exon 20 insertion mutations in EGFR do not respond to tyrosine kinase inhibitors, and were generally treated with platinum-based therapy.
Prilocaine
go.drugbank.com/drugs/DB00750ApprovedInvestigationalA local anesthetic that is similar pharmacologically to lidocaine. Currently, it is used most often for infiltration anesthesia in dentistry. (From AMA Drug Evaluations Annual, 1992, p165)
Mixtures: Realheal-I, Nuvakaan IISynonyms: alpha-n-Propylamino-2-methylpropionanilide, N-(2-Methylphenyl)-2-(propylamino)propanamideLindane
go.drugbank.com/drugs/DB00431ApprovedWithdrawnIn Canada, Lindane is not recommmended as a first-line therapy due to reports of resistance, neurotoxicity, and bone marrow suppression, but has been approved by the FDA as a second-line therapy for topical … treatment of pediculosis capitis (head lice), pediculosis pubis (pubic lice), or scabies in patients greater than two years of age who cannot tolerate or have failed first-line treatment.
Categories: Compounds used in a research, industrial, or household setting